Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06620159

Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

23 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Süleyman demirel üniversitesi tıp fakültesi

Isparta, 32200, Turkey (Türkiye)

About this study

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Covid19 PCR test positive

Exclusion criteria

  • Pregnancy Under 18 years old

Treatment and study plan

Primary outcomes

  1. outcome

    Time frame: 30 days

    The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.

Sponsors and collaborators

Lead sponsor

Suleyman Demirel University

Other

Registry information

Official study title

Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Oct 1, 2024
Registry last updated
Oct 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.